What are the side effects of eloralintide?

In the 48-week phase 2 trial, the most common adverse events were nausea and fatigue, and both tended to rise with dose. Nausea ranged from 11% to 64% across the active arms, compared with 14% on placebo, and it peaked in the fixed 6 mg arm rather than the 9 mg arm. Vomiting and other stomach effects were also reported.

The pattern points to dose escalation design as a study question in its own right. Long-term safety, effects on lean mass and results in more diverse groups remain open, and phase 3 is built to answer them. Eloralintide sold here is a research compound and isn’t for human use. Lot testing is covered on our lab testing page. Shop eloralintide.